2KZ Stock Overview
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Kezar Life Sciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.73 |
| 52 Week High | US$2.80 |
| 52 Week Low | US$0.61 |
| Beta | 0.46 |
| 1 Month Change | -5.16% |
| 3 Month Change | -6.37% |
| 1 Year Change | -64.32% |
| 3 Year Change | -84.49% |
| 5 Year Change | -95.62% |
| Change since IPO | -94.98% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2KZ | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -3.3% | 0.8% | 1.2% |
| 1Y | -64.3% | -24.4% | 2.0% |
Return vs Industry: 2KZ underperformed the German Biotechs industry which returned -24.4% over the past year.
Return vs Market: 2KZ underperformed the German Market which returned 2% over the past year.
Price Volatility
| 2KZ volatility | |
|---|---|
| 2KZ Average Weekly Movement | 13.2% |
| Biotechs Industry Average Movement | 4.9% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 2KZ's share price has been volatile over the past 3 months.
Volatility Over Time: 2KZ's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 58 | Chris Kirk | www.kezarlifesciences.com |
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company’s lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics.
Kezar Life Sciences, Inc. Fundamentals Summary
| 2KZ fundamental statistics | |
|---|---|
| Market cap | €54.78m |
| Earnings (TTM) | -€95.23m |
| Revenue (TTM) | €6.54m |
8.4x
P/S Ratio-0.6x
P/E RatioIs 2KZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2KZ income statement (TTM) | |
|---|---|
| Revenue | US$7.00m |
| Cost of Revenue | US$77.09m |
| Gross Profit | -US$70.08m |
| Other Expenses | US$31.79m |
| Earnings | -US$101.87m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.40 |
| Gross Margin | -1,001.21% |
| Net Profit Margin | -1,455.29% |
| Debt/Equity Ratio | 5.4% |
How did 2KZ perform over the long term?
See historical performance and comparison